伊朗分枝桿菌感染的案例報(bào)道及文獻(xiàn)分析4

打開(kāi)文本圖片集

中圖分類(lèi)號(hào)R915 文獻(xiàn)標(biāo)志碼A 文章編號(hào) 1001-0408（2025）15-1931-05

DOI10.6039/j.issn.1001-0408.2025.15.20

Casereportand literatureanalysisofMycobacteriumiranicuminfection

ZHANG Yewen1，2，LUO Chengling'，JIANG Wengao’，CHEN Min，DU Qian4，YAO Wei3，LIU Songqing4，XI Xin4 （1.College of Pharmacy，Chongqing Medical University，Chongqing 401120，China；2.School of Basic Medicine and Clinical Pharmacy，China Pharmaceutical University，Nanjing 210oo0，China；3.Dept.of Respiratory Medicine，Third Afiliated Hospital of Chongqing Medical University，Chongqing 401120，China; 4.Dept.of Pharmacy，Third Afiliated Hospital of Chongqing Medical University，Chongqing 401120，China）

ABSTRACTOBJECTIVEToofferareference forthe treatmentofMycobacteriumiranicum infectionbyanalyzingthediagnosis and managementofasinglecasealongside literature-reportedcases.METHODSThroughcasereportandliteraturereviews，this studysynthesizedtheclinicalfeatures，therapeuticregimens，andpatientoutcomesofthoseinfectedwithM.iranicum.RESULS Inthesinglecasedocumentedinthisreport，subsequenttolinicalpharmacists’involvementintheconsultation，thepatientwas prescribed a therapeutic regimen comprising levofloxacin（ 0.5g ，qd，ivgtt） + Clarithromycin sustained-release tablets （ 1000mg ， qd，po） + Ethambutol tablets （ 0.75g ，qd，po）.The patient exhibited clinical improvement and was discharged after treatment. Thisarticle integrated12 published studies，encompassing 13 patients（7male and6 female），of whom 69.23% wereaged ?50 years.Patients infected with M. iranicum exhibited non-specific clinical manifestations and imaging features，with pulmonary infection as the primary presentation.Antimicrobial susceptibility test revealed that M. iranicum was susceptible to multiple agents， includingamikacin，clarithromycin，linezolid，andethambutol.Thethre-drugcombinationtherapywasthemostfrequently employed regimen. In terms of clinical outcomes，there were 9 cases（ 69.23% ）of clinical cure，3 cases （23.08% ）of bacteriological negativity conversion，and 1 case（ 7.69% ）of treatment failure. CONCLUSIONS For M. iranicum infection，a triple-drugtherapeuticregimenconsistingof threeagentswithdistinct mechanismsofactionselectedfromamikacin，

clarithromycin， moxifloxacin，levofloxacin，minocycline， ethambutol， and otherrelevant drugsmayrepresenta relativelyoptimal strategy.

KEYWORDSMycobacterium iranicum; nontuberculous mycobacteria；pharmacotherapy；literaturereview

隨著細(xì)菌分離鑒定技術(shù)的不斷進(jìn)步，新的非結(jié)核分枝桿菌（nontuberculousmycobacteria，NTM）菌種不斷被發(fā)現(xiàn)。（剩余8615字）